Testing for inherited and acquired thrombophilias adds to the cost of care of patients with Venous Thromboembolism (VTE), though results may not influence Patient management. This is a single-center, retrospective study conducted at Emory University Hospitals from January to December 2015 to (1) determine the pattern of Thrombophilia testing in patients with VTE, (2) study the impact of results of Thrombophilia testing on clinical decision-making, and (3) determine the direct costs of Thrombophilia testing in patients with VTE. Of the 266 eligible patients, 189 (71%) underwent testing; 51 (26.9%) tested positive and the results impacted management in 32 (16.9%) of tested patients. Patient undergoing testing were more likely to be younger than 40 years (30.9 vs. 18.2%), have had prior pregnancy loss (9.0 vs. 0%), or known family history of hypercoagulability (24.9 vs. 10.4%), and were less likely to have had provoked VTE (37 vs. 79.2%). The most common thrombophilias tested were antiphospholipid syndrome (60.1%), factor V Leiden (59.7%), and prothrombin gene mutation (57.5%). Direct costs of Thrombophilia testing were $2,364.32 per Patient, $12,331.55 to diagnose 1 positive, and $19,653.41 per Patient-management affected. We noted significant variability in selection of patients and panel of tests, sparse utilization of test results in Patient management, but high cost associated with Thrombophilia testing in patients with VTE. With guidelines advocating selective use of Thrombophilia testing and attention to potential impact of test results in Patient management, we propose the need for measures at institutional levels to improve test-ordering practices.
